We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Zimmer (ZBH) Down 12.5% Since Last Earnings Report?
Read MoreHide Full Article
It has been about a month since the last earnings report for Zimmer Biomet (ZBH - Free Report) . Shares have lost about 12.5% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Zimmer due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Zimmer Biomet Gains From Strength in Knee Arm in Q4
Zimmer Biomet posted fourth-quarter 2019 adjusted earnings per share (EPS) of $2.30, surpassing the Zacks Consensus Estimate by 1.8%. The figure also improved 5.5% year over year.
On a reported basis, EPS came in at $1.54 against the year-ago loss of $4.42 per share.
For the full year, adjusted earnings improved 3% to $7.87 from the 2018-level and also exceeded the Zacks Consensus Estimate by 0.5%.
Revenue Details
Fourth-quarter net sales of $2.13 billion increased 3% (up 3.9% at constant exchange rate or CER) year over year. The figure also exceeded the Zacks Consensus Estimate of $2.11 billion by 0.8%.
Full-year net sales of $7.98 billion increased 0.6% from the 2018 figure (up 2.2% at CER). This too topped the Zacks Consensus Estimate by 1%.
During the fourth quarter, sales generated in the Americas totaled $1.29 billion (up 2.4% year over year at CER) while the same in EMEA (Europe, the Middle East and Africa) grossed $471 million (up 1.4% year over year at CER). Asia-Pacific registered 8.6% growth at CER to $367 million.
Segments
Sales in the Knees unit improved 4.9% year over year at CER to $761 million. Hips recorded a 3.2% increase at CER from the prior-year quarter’s $511 million. Revenues in the S.E.T. (Surgical, Sports Medicine, Foot and Ankle, Extremities and Trauma) unit rose 3.1% year over year to $474 million.
Among other segments, Spine & CMF (Craniomaxillofacial) inched up 0.2% at CER to $197 million while Dental rose 5% to $109 million. Other revenues were down 7.7% to $74 million.
Margins
Gross margin after excluding intangible asset amortization came in at 72.6%, reflecting an expansion of 78 bps in the fourth quarter. Selling, general and administrative expenses dropped 11.7% to $882.2 million. Research and development expenses rose 19.7% to $121.1 million. Adjusted operating margin grew 669 bps to 25.4% during the quarter.
Cash Position
Zimmer Biomet exited the year with cash and cash equivalents of $617.9 million compared with $542.8 million at 2018 end. Long-term debt at the end of 2019 totaled $8.22 billion, reflecting a reduction from $8.94 billion at the end of 2018.
Cumulative net cash provided by operating activities at the end of 2019 was $1.59 billion compared with $1.75 billion a year ago.
2020 Guidance
The company provided its 2020 guidance. Full-year sales growth is projected in the range of 2.5-3.5% compared with the 2019 expectation. Management noted that there will be an overall neutral impact from currency movement in 2020 (expectedto be negative in the first half of the year and slightly positive in the second half). Adjusted EPS for 2020 is envisioned in the $8.15-$8.45 band.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in estimates review.
VGM Scores
At this time, Zimmer has a subpar Growth Score of D, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Zimmer has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Zimmer (ZBH) Down 12.5% Since Last Earnings Report?
It has been about a month since the last earnings report for Zimmer Biomet (ZBH - Free Report) . Shares have lost about 12.5% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Zimmer due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Zimmer Biomet Gains From Strength in Knee Arm in Q4
Zimmer Biomet posted fourth-quarter 2019 adjusted earnings per share (EPS) of $2.30, surpassing the Zacks Consensus Estimate by 1.8%. The figure also improved 5.5% year over year.
On a reported basis, EPS came in at $1.54 against the year-ago loss of $4.42 per share.
For the full year, adjusted earnings improved 3% to $7.87 from the 2018-level and also exceeded the Zacks Consensus Estimate by 0.5%.
Revenue Details
Fourth-quarter net sales of $2.13 billion increased 3% (up 3.9% at constant exchange rate or CER) year over year. The figure also exceeded the Zacks Consensus Estimate of $2.11 billion by 0.8%.
Full-year net sales of $7.98 billion increased 0.6% from the 2018 figure (up 2.2% at CER). This too topped the Zacks Consensus Estimate by 1%.
During the fourth quarter, sales generated in the Americas totaled $1.29 billion (up 2.4% year over year at CER) while the same in EMEA (Europe, the Middle East and Africa) grossed $471 million (up 1.4% year over year at CER). Asia-Pacific registered 8.6% growth at CER to $367 million.
Segments
Sales in the Knees unit improved 4.9% year over year at CER to $761 million. Hips recorded a 3.2% increase at CER from the prior-year quarter’s $511 million. Revenues in the S.E.T. (Surgical, Sports Medicine, Foot and Ankle, Extremities and Trauma) unit rose 3.1% year over year to $474 million.
Among other segments, Spine & CMF (Craniomaxillofacial) inched up 0.2% at CER to $197 million while Dental rose 5% to $109 million. Other revenues were down 7.7% to $74 million.
Margins
Gross margin after excluding intangible asset amortization came in at 72.6%, reflecting an expansion of 78 bps in the fourth quarter. Selling, general and administrative expenses dropped 11.7% to $882.2 million. Research and development expenses rose 19.7% to $121.1 million. Adjusted operating margin grew 669 bps to 25.4% during the quarter.
Cash Position
Zimmer Biomet exited the year with cash and cash equivalents of $617.9 million compared with $542.8 million at 2018 end. Long-term debt at the end of 2019 totaled $8.22 billion, reflecting a reduction from $8.94 billion at the end of 2018.
Cumulative net cash provided by operating activities at the end of 2019 was $1.59 billion compared with $1.75 billion a year ago.
2020 Guidance
The company provided its 2020 guidance. Full-year sales growth is projected in the range of 2.5-3.5% compared with the 2019 expectation. Management noted that there will be an overall neutral impact from currency movement in 2020 (expectedto be negative in the first half of the year and slightly positive in the second half). Adjusted EPS for 2020 is envisioned in the $8.15-$8.45 band.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in estimates review.
VGM Scores
At this time, Zimmer has a subpar Growth Score of D, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Zimmer has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.